Collaboration amid the unknown: Heidi’s path to partnership in oncology research
When Heidi Hoppe began her career more than two decades ago, she didn’t plan on becoming the Senior Director of Project Delivery for Biotech at one of the world’s largest CROs. She hadn’t planned on being in the industry at all. She was finishing nursing school when her mother, who worked in biopharma, nudged her toward the industry.
Her mother’s referral directed her to an agency that gave Heidi her first industry placement. She organised paper case report forms at a pharmaceutical company jointly operated by Takeda and Abbott. Within six months, she was authoring Phase 1 protocols. Heidi’s drive to grow and tackle challenges was the springboard for the next 26 years of her professional life, pushing her into new fields, across biopharma and CRO organisations, and into biotech and oncology specialisations. Her journey has also been shaped by personal experience, and a profound appreciation for what it means to work together in service of patients.
Reorienting research
Early in Heidi’s clinical research career, a family health crisis reoriented her professional outlook and brought a new perspective to her work. Heidi’s niece was diagnosed with acute lymphoblastic leukaemia. “She was diagnosed two weeks before her third birthday. Now she is cancer free and turning 27,” Heidi recalls. “Watching her go through treatment changed my understanding of research from the patient and caregiver perspective. It gave me a more holistic view.”
That experience, combined with a desire to stay closely involved in her niece’s care, led Heidi to seek remote opportunities and ultimately influenced her move into oncology-focused roles. Her professional and personal worlds converged in a way that sharpened her sense of purpose and deepened her resolve to improve outcomes for patients through more thoughtful, effective trial execution.
Collaboration as the foundation
Today, Heidi spends most of her time focused on one thing: effective partnership. In her role in Project Delivery and having come from Clinical Operations, she understands the value of a truly collaborative relationship with sponsors and how it can be the lynchpin of a smooth, efficient project execution amid a complex clinical development process.
“We are in an industry that constantly faces challenges,” she says. “But when you have a partner sitting across the table from you instead of a vendor, you move through those challenges more effectively. That is the mindset I try to instil in every engagement.”
Rather than defaulting to transactional sponsor-CRO dynamics, Heidi and her teams prioritise partnership models that enable transparency, mutual accountability and shared goals. Her approach is grounded in establishing clear communication pathways and governance structures that anticipate issues before they escalate.
In a recent example, a sponsor engaged ICON to help turn around a struggling program. The first step to success? “We listened. Really listened,” says Heidi. The team had to get a clear picture of the pain points and then co-created a governance model that specifically addressed their concerns. The impact was immediate, and it improved delivery and trust across an entire study portfolio.
These are the kind of wins that energise Heidi. Although she spends most of her time on the phone with clients and project teams, aligning, problem-solving and looking for ways to move forward together, seeing the progress they make with true collaboration is incredibly rewarding.
Making room for the unexpected
Heidi’s strong sense of relationship building benefits sponsors, but it has also made a friend of uncertainty. Uncertainty is the only certainty, as the adage goes, and Heidi is well adapted for it.
“If you have an aversion to change, this is probably the wrong industry,” she says. “You have to be willing to evolve and bring your team with you.”
This sense of openness—to new ideas, new roles and new challenges—has shaped her career and gives her the ability to support sponsors as they navigate the industry. And the industry is certainly on a trajectory for further transformation. Continued macroeconomic pressures will influence development strategies, while technologies such as AI offer promise for enhanced efficiency and decision-making. In the face of these changes, Heidi remains optimistic.
“At the end of the day, biotech sponsors are hiring us for our expertise,” she notes. Leveraging that expertise requires trust. It requires dialogue. And it requires remembering that our shared mission is to get therapies to patients faster and more responsibly.
Heidi’s career started with a dose of chance, has been propelled by ambition, redirected by familial hardship, and catalysed by collaboration and a willingness to embrace the unexpected. As she knows well in her role with ICON Biotech, sometimes it’s the unexpected that pushes us forward the most.
Connect with us to learn how ICON’s commitment to collaborative partnerships can benefit your biotech program.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Decoding AI in software as a medical device (SaMD)
-
Software as a medical device (SaMD)
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
-
Blended solutions insights
-
Clinical trials in Japan: An enterprise growth and management strategy
-
How investments in supply of CRAs is better than competing with the demand for CRAs
-
The evolution of FSP: not just for large pharma
-
Embracing a blended operating model
-
Observations in outsourcing: Survey results show a blended future
-
Clinical trials in Japan: An enterprise growth and management strategy
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Behind Biotech: Stories of science and resilience
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel